Emerging issues in antibiotic resistance in blood-borne infections

American Journal of Respiratory and Critical Care Medicine

Volumn 162, Issue 5, 2000, Pages 1610-1616

  Karam, G H ^a   Heffner, J E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; DRUG CHOICE; DRUG USE; HUMAN; INFECTION CONTROL; INTENSIVE CARE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

EID: 0033711403     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.162.5.pc10-00     Document Type: Review

References (76)

1. Drug resistance in intensive care units
2. Rational empiric antibiotic prescription in the ICU
3. Antibiotic usage and prescribing policies in the intensive care unit
4. Practices to improve antimicrobial use at 47 US hospitals: The status of the 1997 SHEA/IDSA position paper recommendations. Society for Healthcare Epidemiology of America/Infectious Diseases Society of America
5. Antimicrobial resistance in intensive care units
6. Clinical aspects of antimicrobial resistance
7. Antibiotic resistance in ICUs: A multifaceted problem requiring a multifaceted solution
8. Control of a prolonged outbreak of extended-spectrum β-lactamase-producing enterobacteriaceae in a university hospital
9. Randomized, controlled trial of selective digestive decontamination in 600 mechanically ventilated patients in a multidisciplinary intensive care unit
10. A multicentre survey of hand hygiene practice in intensive care units
11. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals
12. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance
13. Enterococci and vancomycin resistance
14. The challenges of emerging infectious diseases
15. Vancomycin-resistant Staphylococcus aureus: Infection control considerations
16. Computer-assisted prescribing and its impact on resistance
17. A computer-assisted management program for antibiotics and other antiinfective agents
18. The microbial genetics of antibiotic cycling
19. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy
20. Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin
21. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients
22. Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes
23. CDC NNIS System. National Nosocomial Infections Surveillance (NNIS) system report, data summary
24. Nosocomial infections in medical intensive care units in the United States
25. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
26. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE Phase 2
27. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneuraoniae Therapeutic Working Group
28. Extended-spectrum β-lactamases: A call for improved detection and control
29. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes
30. Emerging antibiotic resistance
31. Novel plasmid-mediated β-lactamases in Enterobacteriaceae: Emerging problems for new β-lactam antibiotics
32. Laboratory capacity to detect antimicrobial resistance
33. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility
34. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins
35. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: A case-control and molecular epidemiologic investigation
36. Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: Epidemiology and risk factors for acquisition
37. Antimicrobial-drug resistance
38. Treatment failure due to extended-spectrum β-lactamase
39. Efficacy of different β-lactams against an extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain in the rat intraabdominal abscess model
40. In vitro activities of various β-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins
41. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: A 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group
42. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia
43. Antibiotic resistance - Squeezing the balloon?
44. Clinical characteristics and molecular epidemiology associated with imipenem-resistant
45. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella
46. Virulence of enterococci
47. Nosocomial infection surveillance
48. Resistance to glycopeptides in enterococci
49. Enterococci
50. Resistant enterococci: A prospective study of prevalence, incidence, and factors associated with colonization in a university hospital
51. Cephalosporins as risk factor for nosocomial Enterococcus faecalis bacteremia: A matched case-control study
52. Vancomycin-resistant enterococci in intensive care units: High frequency of stool carriage during a non-outbreak period
53. A polycolonal outbreak of predominantly vanB vancomycin-resistant enterococci in northeast Ohio
54. Biliary excretion of piperacillin
55. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: Comparison of clinical features and outcomes
56. Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection
57. Requirement of the VanY and VanX D,D-peptidases for glycopeptide resistance in enterococci
58. Vancomycin-resistant enterococcal infections
59. Quinupristin/dalfopristin (Synercid) treatment of infections caused by vancomycin-resistant Enterococcus faecium (VREF)
60. International conference for the development of a consensus on the management and prevention of severe candidal infections
61. Epidemiology of nosocomial fungal infections, with emphasis on Candida species
62. Candidemia in cancer patients: A prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
63. Treatment of opportunistic fungal infections
64. Fungemia in a cancer hospital: Changing frequency, earlier onset, and results of therapy
65. Fungemia in the immunocompromised host: Changing patterns, antigenemia, high mortality
66. Indications for therapy for fungemia in postoperative patients
67. Current strategies for treating invasive candidiasis: Emphasis on infections in nonneutropenic patients
68. Nosocomial candidemia: Risk factors and attributable mortality
69. Antifungal agents: Chemotherapeutic targets and immunologic strategies
70. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance
71. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
72. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients
73. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after adoption of prophylactic fluconazole
74. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance